Does Daily Supplementation of Lactobacillus Acidophilus MPH734 (Lacto-FreedomTM, or LF), for One Week, Affects Acute (Immediate), Subacute (7 Days), and Post-treatment Discontinuation (30-, 60-, and 90- Day) Lactose Metabolism, Gastrointestinal Symptoms, and Clinical Markers of Inflammation and Safety Compared to a Placebo?

Participants will be included and/or excluded in the study based on the criteria below:

Inclusion Criteria

• Participants will be male or female between the ages of 18-55 years;
• Participants will be apparently healthy and free from disease, as determined by a health history questionnaire;
• Participants will not be excluded if he or she has been clinically diagnosed with a carbohydrate malabsorption disorder, or is or has been prescribed to take prescription or over-the-counter medication for such;
• Participant has self-diagnosed or otherwise avoids consuming dairy, lactose, and other dairy-containing products, or regularly consumes Lactase enzymes for digestive support;
• Participant agrees and can comply with the study protocol;
• Participant provides signed and dated informed consent to participate in the study.

Subject Exclusion Criteria

• Participant is or may be pregnant, is trying to become pregnant, or is breastfeeding;
• Participant is insulin-dependent or -independent diabetic.
• Participant currently uses, or has discontinued the use of nicotine-containing products within twelve (12) months of the start of the study;
• Participant lives or works within an environment that chronically exposes the subject to second-hand smoke;
• Participant currently uses, or has discontinued the use of recreational drugs or medicinal marijuana within twelve (12) months of the start of the study;
• Participant has been clinically diagnosed with a digestive disorder such as gastrointestinal disease, chronic diarrhea or constipation, irritable or inflammatory bowel syndrome, Crohn's disease, or is, or has been prescribed to take prescription or over-the-counter medication for such;
• Participant has ever undergone gastric bypass surgery, or has undergone an abdominal or other gastrointestinal surgery within twelve (12) months of the start of the study;
• Participant is taking, or has taken antibiotic medications within two (2) weeks of the start of the study;
• Participant has undergone a colonoscopy within two (2) weeks of the start of the study, or is scheduled to receive a colonoscopy during the study;
• Participant has undergone a barium study or received an enema within two (2) weeks of the start of the study, or is scheduled to, or receives such during the study;
• Participant is taking, or has taken probiotics within two (2) weeks of the start of the study;
• Participant uses lactose digesting enzymes during the study;
• Participant is taking, or has taken weight loss, prebiotic [e.g., fructo- or galacto-oligosaccharides (FOS or GOS), psyllium, or insulin fiber, etc.], or laxative / stool softener dietary supplements, over-the-counter, or prescription medications within two (2) weeks of the start of the study;
• Participant is allergic to any ingredient present within the dietary supplement or placebo treatment;
• Participant reports any unusual adverse events associated with this study that, in consultation with the study investigators or the participant's doctor recommends removal from the body;
• Participant fails to comply with the study protocol.